A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia

Human Psychopharmacology

Volumn 19, Issue 4, 2004, Pages 265-269

  Kim, Yang Tae ^a   Kang, Byung Jo ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Cognitive function; Olanzapine; Schizophrenia

Indexed keywords

BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; OLANZAPINE; PROPRANOLOL; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MALE; OUTPATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SOMNOLENCE; SPEECH INTELLIGIBILITY; SYMPTOM; VERBAL MEMORY; VISUAL MEMORY; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; BENZODIAZEPINES; COGNITION; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MENTAL RECALL; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; VERBAL BEHAVIOR; VISUAL PERCEPTION;

EID: 3042720289     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.584     Document Type: Article

References (22)

1. Bhana N, Foster RH, Olney R, Plosker GL. 2001. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61: 111-161.
2. Bilder RM, Goldman RS, Volavka J, et al. 2002. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1128.
3. Breier A. 1999. Cognitive deficit in schizophrenia and its neurochemical basis. Br J Psychiatry Suppl 37: 16-18.
4. Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E. 2001. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 18: 45-61.
5. Chengappa KN, Pollock BG, Parepally H, et al. 2000. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20: 311-316.
6. Daniel DG. 1994. Comparison of risperidone and clozapine on clinical and cognitive functions in psychiatric disorders (abstract). Biol Psychiatry 35: 667.
7. Friedman JI, Temporini H, Davis KL. 1999. Pharmacological strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 45: 1-16.
8. Gold JM, Harvey PD. 1993. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 16: 295-312.
9. Gold JM, Randolph C, Carpenter CJ, Goldberg TE, Weinberger DR. 1992. Forms of memory failure in schizophrenia. J Abnorm Psychol 101: 487-494.
10. Goldberg TE, Gold JM. 1995. Neurocognitive functioning in patients with schizophrenia, an overview. In Psychopharmacology, 4th edn. Raven Press: New York; 1245-1257.
11. Goldberg TE, Regland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR. 1990. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 47: 1066-1072.
12. Hagger C, Bucley P, Kenney JT, Friedman L, Ubogy D, Meltzer HY. 1993. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702-712.
13. Harvey PD, Green MF, McGurk SR, Meltzer HY. 2003. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169: 404-411.
14. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 2001. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531.
15. King DJ. 1994. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatr Scand Suppl 38: 53-58.
16. Meltzer HY, MeGurk SR. 1999. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
17. Moore NA. 1999. Olanzapine: preclinical pharmacology and recent findings. Br J Psychiatry Suppl 37: 41-44.
18. Purdon SE, Jones BD, Stip E, et al. 2000. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57: 249-258.
19. Sharma T. 1999. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry Suppl 38: 44-51.
20. Tandon R, Milner K, Jibson MD. 1999. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry Suppl 8: 21-28.
21. Terry AV Jr, Hill WD, Parikh V, Evans DR, Waller JL, Mahadik SP. 2002. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology 164: 360-368.
22. Weinberger DR, Berman KF, Illowsky BP. 1988. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: a new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 45: 609-615.